Cenna Biosciences Inc. Selected to Present at Cavendish Global Health Impact Forum

Share Article

Forum uniquely brings together leading family offices, their foundations and sovereign wealth fund representatives seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

Cenna Bioscience Inc., an emerging biopharmaceutical company focused on the discovery and development of new agents for the treatment of Alzheimer’s disease, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place February 15th to February 18th at the Breakers in Palm Beach, Florida. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, research institutions, and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of family offices, Cavendish Impact Forums are hosted by leading institutions around the world and take place three times each year.

Michael Moffat, Cavendish co-founder and Chief Executive Officer explains, “The theme of our Palm Beach Forum is a ‘Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.’ With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Cenna’s research and scientific insights into the mechanisms responsible for Alzheimer’s disease positions them to make a major contribution to the prevention and treatment of Alzheimer’s disease.”

“We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to stop Alzheimer’s disease in its tracks. Alzheimer’s disease affects one in ten people over the age of 65 worldwide, one in two by age 90. There are 5.4 million people in the US alone that are affected by Alzheimer’s disease and the cost of caring for them is approximately $200 billion per year, said Nazneen Dewji, Ph.D., Founder and CEO. “We welcome the chance to interact with many of world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”

Cavendish Global consists of over 200 leading family offices and foundations from around the world with combined assets of over $260 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world.

About Cenna Biosciences Inc.

Cenna Biosciences is dedicated to the discovery and development of novel drugs to prevent and treat Alzheimer’s disease. Cenna was founded in 2006 as a California C-corporation, to translate over a decade’s academic research at the University of California at San Diego (UCSD) by the inventors of its technology. The proprietary technology addresses the underlying cause of the disease, the inappropriate deposition of the toxic species, ß-amyloid (Aß), in the brains of patients with AD. The Company has developed a novel target and is developing several lead peptide compounds as disease-modifying drug candidates for the treatment of AD. The Intellectual Property that forms the basis of Cenna’s approach is covered by U.S. and foreign Patents, filed by UCSD and exclusively licensed to Cenna by UCSD.

Further information is available on the Company's website, http://www.cennabiosciences.com.

About Cavendish Global
(http://cavendishglobal.com)
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year.

For more information: http://cavendishglobal.com

For Further Information Contact:

Alex Charlton
President, Cavendish Global
alex.charlton@cavendishglobal.com
Tel: +1-917-576-1435

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nazneen Dewji
Cenna Biosciences Inc.
+1 8584560821
Email >
Visit website